{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:45:02Z","timestamp":1788637502958,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Ephrin type-B receptor 4 (EPHB4) is overexpressed on the surface of various tumor cells, including cells from malignant bone and soft-tissue tumors. AP8901 CAR-T cell therapy can specifically recognize and kill EPHB4 receptor-expressing malignant tumor cells by modifying the natural EPHB4 receptor ligand, ephrin B2. AP8901 is being developed via genetic manipulation involving the \u201cpiggyBac transposon\u201d and \u201cgenetically modified feeder cell\u201d methods, which enables the stable expression of CAR proteins in T cells and prevents T cell exhaustion. AP8901 has demonstrated therapeutic efficacy and tolerability in mice transplanted with rhabdomyosarcoma cells. We planned a phase I study to evaluate the safety and efficacy of AP8901 for metastatic solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a single-center, single-arm, dose-escalation, phase I study to evaluate the safety, tolerability, pharmacokinetics\/pharmacodynamics, and preliminary anti-tumor activity of a single intravenous dose of AP8901 in patients with Ewing sarcoma or solid tumors expressing the EPHB4 receptor. Key inclusion criteria include the following: subjects with histologically diagnosed Ewing sarcoma or solid tumor with confirmed metastasis or recurrence\/no standard treatment for metastasis or recurrence, or refractory or intolerant to standard treatment; measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; recent biopsy or surgical resection specimens with prescreening immunohistochemistry positive for EPHB4 in \u22651% of tumor cells; ECOG performance status 0 or 1; and subjects expected to survive \u22653 months from the date of enrollment. This study is being conducted at the National Cancer Center Hospital East, Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The advantage of AP8901 is that it is expected to prevent T cell exhaustion and maintain its anti-tumor effect. This phase 1 study of AP8901 will provide new evidence for the application of this novel CAR-T cell therapy in patients with solid tumors, including Ewing sarcoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1633324","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:11:53Z","timestamp":1754453513000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Trial in progress: phase I study of non-viral gene-modified CAR-T cell therapy for malignant solid tumors expressing EPHB4 receptor (CARTiEr)"],"prefix":"10.3389","volume":"15","author":[{"given":"Chikako","family":"Funasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Fuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genichiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nakatsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konomi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yozo","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yagyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","volume-title":"Cancer Statistics","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/COAYA.S61451","article-title":"Ewing sarcoma in adolescents and young adults: diagnosis and treatment","volume":"4","author":"Davis","year":"2014","journal-title":"Clin Oncol Adolesc Young Adults"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S170585","article-title":"Management of recurrent Ewing sarcoma: challenges and approaches","volume":"12","author":"Van Mater","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.23040","article-title":"Risk of recurrence and survival after relapse in patients with Ewing sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1242\/dev.127.2.269","article-title":"The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis","volume":"127","author":"Helbling","year":"2000","journal-title":"Development"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401381101","article-title":"Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth","volume":"101","author":"Noren","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B7","unstructured":""},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183161","article-title":"EphB4\/EphrinB2 therapeutics in rhabdomyosarcoma","volume":"12","author":"Randolph","year":"2017","journal-title":"PloS One"},{"key":"B9","article-title":"Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma","volume":"28","author":"Berardi","year":"2008","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1403608111","article-title":"PDGFR\u03b2 reverses EphB4 signaling in alveolar rhabdomyosarcoma","volume":"111","author":"Aslam","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067668","article-title":"The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target","volume":"8","author":"Ferguson","year":"2013","journal-title":"PloS One"},{"key":"B12","first-page":"5997","article-title":"The role of EphB4 and IGF-IR expression in breast cancer cells","volume":"8","author":"Huang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050889","article-title":"Receptor tyrosine kinase EphB4 is a survival factor in breast cancer","volume":"169","author":"Kumar","year":"2006","journal-title":"Am J Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3232","article-title":"Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression","volume":"69","author":"Kumar","year":"2009","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0915","article-title":"Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers","volume":"73","author":"Hasina","year":"2013","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl414","article-title":"Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers","volume":"18","author":"Alam","year":"2007","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl414","article-title":"The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome","volume":"96","author":"Kumar","year":"2007","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2667","article-title":"EphB4 expression and biological significance in prostate cancer","volume":"65","author":"Xia","year":"2005","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105326","article-title":"The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder","volume":"9","author":"Li","year":"2014","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-269","article-title":"EphB4 as a therapeutic target in mesothelioma","volume":"13","author":"Liu","year":"2013","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.03.011","article-title":"Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype","volume":"21","author":"Nakamura","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.03.001","article-title":"Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma","volume":"20","author":"Kubo","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1291","article-title":"A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells","volume":"10","author":"Yagyu","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1633324\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:11:54Z","timestamp":1754453514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1633324\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":27,"alternative-id":["10.3389\/fonc.2025.1633324"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1633324","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1633324"}}